Clinical Study

A Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial Of An Autologous Tumor Lysate (Tl) + Yeast Cell Wall Particles (Ycwp) + Dendritic Cells (Dc) Vaccine Vs Unloaded Ycwp + Dc In Stage III And Stage Iv (Resected) Melanoma To Prevent Rec

Posted Date: Oct 25, 2017

  • Investigator: Jeffrey Sussman
  • Co-Investigator: Bridget Kinne
  • Specialties: Hematology/Oncology, Oncology, Cancer, Skin Cancer
  • Type of Study: Drug

The purpose of this study is to (1) produce and test a vaccine that is made from patient’s tumor cells and white blood cells to determine if it can prevent melanoma recurrence; (2) to look at the safety of the vaccine; and (3) to look at the immune system

Criteria:

To Be Eligible For This Study, Patients Must Be Being Treated For Stage Iii Or Stage Iv Melanoma That Will Be Surgically Removed (Resected) And At High Risk For Recurrence.

Keywords:

Elios, Cancer, Vaccine, Melanoma, Null

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.